
==== Front
BMJ Case Rep
BMJ Case Rep
bmjcr
bcr
BMJ Case Reports
1757-790X
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

39214573
10.1136/bcr-2023-258468
bcr-2023-258468
Case Report
Case Reports: Unusual presentation of more common disease/injury
Cavitary lung lesions caused by Pneumocystis jirovecii in a patient with myelofibrosis on ruxolitinib
http://orcid.org/0000-0003-4914-3910
https://twitter.com/RitterAustinN
Ritter Austin austin.ritter@gmail.com
1
Kensey Nicholas nicholas_kensey@brown.edu
1
Higgs James Higgs@KentRI.org
2
Zainah Hadeel hzainah@kentri.org
2
1 Kent Hospital Internal Medicine, Brown University, Warwick, Rhode Island, USA
2 Department of Infectious Diseases, Kent Hospital, Warwick, Rhode Island, USA
None declared.

Dr; austin.ritter@gmail.com
2024
30 8 2024
30 8 2024
17 8 e25846813 8 2024
Copyright © BMJ Publishing Group Limited 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Summary

We report a rare case of a patient with Janus kinase 2-positive myelofibrosis on ruxolitinib, presenting with indolent pneumonia and cavitary lung lesions. Initial transthoracic biopsy was non-specific, but thoracoscopic biopsy revealed necrotising granulomatous disease caused by Pneumocystis jirovecii pneumonia (PJP). The patient, initially treated with trimethoprim–sulfamethoxazole, was switched to atovaquone due to gastrointestinal intolerance. Given the patient’s immunosuppression and extensive cavitary lesions, an extended course of atovaquone was administered, guided by serial imaging, resulting in clinical and radiological improvement. Unfortunately, the patient later passed away from a severe SARS-CoV-2 infection before complete radiographic resolution was observed. This case highlights the importance of recognising atypical PJP presentations causing granulomatous disease in immunosuppressed patients. While rare, documenting such cases may improve diagnosis using less invasive methods and help determine optimal treatment durations for resolution of these atypical infections.

immunology
infectious diseases
haematology (incl blood transfusion)
pneumonia (respiratory medicine)
haematology (drugs and medicines)
==== Body
pmcBackground

Pneumocystis jirovecii pneumonia (PJP) is a life-threatening pulmonary infection that predominantly affects immunocompromised individuals. In patients with HIV, the risk factors and typical presenting signs of PJP are relatively well understood, facilitating improved prevention and treatment strategies. However, in non-HIV-infected individuals, the risk, presentation and management of PJP are less known, leading to potential delays in diagnosis and treatment.1 2

Patients with myelofibrosis treated with Janus kinase inhibitors constitute one such immunocompromised group in which the presentation and optimal management of PJP remain uncertain. Myelofibrosis contributes to an immunosuppressive state due to cell line disturbances, a reduced capacity for infection recovery and diminished spleen function.3 Furthermore, Janus kinase inhibitors such as ruxolitinib used to treat myelofibrosis may independently affect infection risk by downregulating critical immune and inflammatory signalling pathways and disrupting the activation of numerous immune cells.4 Ruxolitinib has been associated with multiple opportunistic infections, including PJP, cryptococcus, aspergillosis, non-tuberculous mycobacteria and cytomegalovirus.5 6

Although PJP typically presents more acutely in non-HIV-infected individuals, indolent presentations are now recognised in patients with only mild-to-moderate immunosuppression. Specifically, PJP may present with nodular or cavitary lesions caused by granulomatous inflammation in such patients. Enhancing the recognition of atypical PJP presentations in patients with various degrees of immunosuppression is crucial due to the increasing prevalence of immunosuppression and resultant opportunistic infections.79

Case presentation

A female patient in her mid-60s with well-controlled type 2 diabetes mellitus and JAK-2-positive postpolycythemic myelofibrosis presented with a persistent cough, night sweats and fatigue progressively worsening over the prior 2 months. On examination, she appeared fatigued and mildly dyspneic with a temperature of 38.0°C. Her vital signs were otherwise normal with blood pressure 133/84 mm Hg, pulse 88 beats per minute, respiratory rate 18 breaths per minute and oxygen saturation 98% on room air. Lung auscultation revealed clear breath sounds bilaterally with no wheezes, rales or rhonchi. Her laboratory workup showed a white blood cell count of 23.1×10⁹/L (85% myeloid), haemoglobin of 111 g/L (normal 120–160), platelets of 220×10⁹/L (normal 150–450×10⁹/L), lactate dehydrogenase of 345 international units/L (normal 140–271), IgG of 281 mg/dL (normal 635–1741), IgA of 25 mg/dL (normal 66–433) and IgM was<20 mg/dL (normal 45–281). She was treated with ruxolitinib (20 mg two times per day) for 9 years. Severe cytopenias complicated her treatment course, along with recurrent left lower extremity ulcers due to varicella zoster, abundant recurrent human papillomavirus warts on her hands, recurrent vaginal intraepithelial neoplasia and an episode of disseminated herpes simplex virus.

Investigations

An X-ray of the chest revealed patchy bilateral infiltrates with multiple new lung masses (figure 1), leading to her admission for pneumonia. High-resolution CT of the chest showed numerous masses throughout both lung fields, with the largest in the upper lobes with evidence of cavitation (figure 2A). Further initial workup included blood cultures, which were negative after 5 days of incubation. Urine antigen tests for Streptococcus pneumoniae and Legionella pneumoniae were negative, as was methicillin-resistant Staphylococcus nasal screening. Tuberculosis was initially ruled out with acid-fast bacilli (AFB) smear and culture, all of which were negative on three separate sputum samples collected during the initial hospitalisation. She was discharged home with a short course of antibiotics for community-acquired pneumonia, which could not be completely ruled out despite the atypical presentation and imaging findings.

Figure 1 X-ray of the chest showing new patchy bilateral infiltrates and multiple lung masses.

Figure 2 Axial section from CT scans of the chest showing (A) bilateral infiltrates and multiple cavitary lesions at initial diagnosis and (B) after 4 months of treatment with atovaquone.

The patient remained symptomatic, and a follow-up percutaneous right upper lobe biopsy performed 15 weeks after initial presentation showed rare loosely necrotising granulomas. However, a detailed pathologic workup was otherwise non-specific. The biopsy results were reviewed by pathologists at a tertiary care centre in a specialised thoracic pathology consensus conference, which confirmed the non-diagnostic nature of the findings. A repeat transthoracic or transbronchial biopsy was considered. However, given the diffuse nature of the lung lesions and the wish for a prompt diagnosis after persistent debilitating symptoms, a shared decision was made to pursue video-assisted thoracoscopic surgery. This surgery was performed 27 weeks after the initial presentation and included a wedge resection of a portion of the lingula.

Perioperative laboratory workup prior to the thoracoscopy showed negative galactomannan and β-D-glucan was >500 pg/mL (normal: <60). The antinuclear antibody titre was <1:80, and immunofluorescence studies were negative for cytoplasmic or perinuclear antineutrophilic autoantibodies. The patient experienced a transient episode of hypercalcaemia for 2 weeks following the wedge resection procedure, with total calcium reaching a maximum of 11.9 mg/dL, parathyroid hormone (PTH) at 7 pg/mL (normal: 12–88), 25-hydroxy vitamin D at 46 ng/mL (normal: 30–95), and ionised calcium at 1.4 mmol/mL (normal: 1.2–1.38).

The wedge resection pathology revealed acute organising bronchopneumonia with necrotising granulomatous inflammation and foamy eosinophilic proteinaceous material (figure 3A). Periodic acid-Schiff, mucicarmine and AFB stains were negative. Grocott’s methenamine stain showed oval, crescent and helmet-shaped non-budding yeast forms (4–5 µm), most suggestive of PJP (figure 3B). Mycobacterium culture of lung tissue was negative as were three repeat AFB smears and cultures from sputum. Additionally, 1 week following discharge after the wedge resection, an outpatient induced sputum sample was obtained that was negative for Mycobacterium tuberculosis via nucleic acid amplification testing.

Figure 3 H&E stain showing granulomatous lung tissue from lingular specimen from patient (A) and Grocott’s methenamine stain from same tissue showing non-budding yeast forms consistent with Pneumocystis jirovecii pneumonia (B).

Differential diagnosis

The differential diagnosis for cavitary lung lesions is broad, encompassing malignancies, autoimmune causes and infectious diseases.10 The presence of multiple nodules and the patient’s immunocompromised status initially raised concerns for metastatic disease and lymphoma. However, the granulomatous tissue results from the initial lung biopsy made neoplasms, such as lymphoma less likely. Vasculitides, such as granulomatous polyangiitis, were considered less likely based on negative antinuclear antibody and antineutrophil cytoplasmic autoantibody tests. Sarcoidosis was also deemed less likely due to the absence of significant adenopathy in the chest. Fungal infections were highly suspected due to the patient’s high β-D-glucan level. Mycobacterial infections were also strongly considered due to their association with ruxolitinib.4 A thorough pathologic examination assisted in narrowing our diagnosis, with mycobacterium assessed to be unlikely based on multiple negative mycobacterium cultures; histoplasmosis was less likely due to the absence of intracellular organisms; blastomycosis and coccidioidomycosis were less likely given smaller size of organisms present; Candida and Aspergillus were less likely as no budding or hyphae were seen; and Cryptococcus was less likely based on negative periodic acid-Schiff and mucicarmine staining results.

Treatment

Immediately after diagnosis of PJP on biopsy, the patient started on trimethoprim–sulfamethoxazole (TMP-SMX) 160/800 mg three times per day. Concurrently, ruxolitinib was tapered to 5 mg two times per day due to cytopenias. Two intravenous immunoglobulin infusions were attempted but discontinued due to severe chills during administration. Given the patient’s immunocompromised state and the lack of guidelines for treating cavitary PJP lesions, a prolonged course of antibiotics was planned with interval imaging to monitor granuloma resolution.

Initial treatment with TMP-SMX proved unsuccessful due to severe nausea and vomiting, significantly limiting the patient’s ability to tolerate the medication. A repeat CT scan of the chest after 4 weeks of attempted treatment with TMP-SMX showed no change in the number or size of cavitary lesions. Consequently, treatment was switched to atovaquone 750 mg twice daily. The patient tolerated atovaquone well without significant gastrointestinal side effects and her symptoms began to improve significantly within days to short weeks after starting atovaquone therapy.

Outcome and follow-up

After 9 weeks of atovaquone treatment, imaging revealed resolution of cavitation and reduced pulmonary nodules (figure 2B). Despite this improvement, significant lung involvement persisted, prompting an extension of treatment for an additional 8 weeks. The patient continued to improve symptomatically and never required supplemental oxygen. Unfortunately, 26 weeks after initiating atovaquone treatment, just as the patient was becoming more active in the community, she contracted SARS-CoV-2. This additional infection led to severe respiratory failure, necessitating intensive care and ventilatory support. CT angiography of the chest showed extensive bilateral multifocal ground glass and consolidative airspace diseases; no pulmonary nodules were observed on the CT scan, though extensive ground glass opacities may have obscured them. Bronchoalveolar lavage revealed no Pneumocystis or fungal elements on periodic acid-Schiff or grocott’s methenamine stains and a negative Pneumocystis PCR. Despite aggressive treatment for COVID-19, the patient developed multiorgan failure and passed away after transitioning to comfort-focused care.

Discussion

Review of similar cases

PJP typically presents with symmetric, diffuse interstitial infiltrates but, on rare occasions, can form nodular or cavitary lesions,10 including necrotising granulomas.1117 We have identified two previous case reports of PJP associated with ruxolitinib,18 19 both of which report more common findings of interstitial infiltrates. Although Lee et al19 also reported nodular changes in a patient with PJP on ruxolitinib, to our knowledge, this is the first case report of confirmed necrotising granulomatous disease associated with myelofibrosis or ruxolitinib.

Pathophysiology

Granuloma formation from PJP is suspected to occur first as nodules that may progress to cavitary lesions through ischaemic necrosis from the invasion of Pneumocystis into vascular lumina or elastolytic proteases liberated by activated macrophages. The formation is generally attributed to host factor differences, particularly CD4, CD8 and Th17 activity,12 20 all of which may be affected by ruxolitinib.4 Additional factors associated with developing granulomatous diseases include exposure time for Pneumocystis glycoproteins, absence of IgA Pneumocystis antibodies and prior Pneumocystis exposure. Genotypic variation of Pneumocystis, once thought to play a role, is now considered less likely to contribute to the development of granulomas.21

Diagnostics

Physicians managing immunocompromised patients, such as those on ruxolitinib, must be aware of the less common nodular or cavitary PJP presentations to avoid delayed or missed diagnoses.1 Cavitary lesions caused by tuberculosis may present similarly,22 but if acid-fast staining and mycobacterial cultures are negative, PJP should be considered as a cause of the cavitations. Coinfections with tuberculosis and PJP may also occur.23 24 Notably, as observed in our case, PTH-independent hypercalcaemia is associated with granulomatous PJP infections and should raise suspicion for this diagnosis.2527

β-D-glucan is a helpful first test to check when granulomatous PJP is suspected and may adequately rule out a diagnosis of PJP if the pretest probability is low.28 Lactate dehydrogenase has traditionally been used as a biomarker for PJP but a meta-analysis suggests that it has a poor sensitivity and specificity for the diagnosis of PJP overall.29 Specificity of lactate dehydrogenase is expected to be particularly low in patients with high cell turnover from haematologic malignancies.12

A moderate-to-high pretest probability warrants checking for PJP in sputum or bronchoalveolar lavage specimens. Microscopic examination of sputum or lavage specimens may be sufficient to detect PJP yeast forms and make a diagnosis. However, the concentration of PJP tends to be lower in the sputum of non-HIV patients,30 likely reducing the sensitivity of microscopy even with efforts to induce sputum to increase the sample volume.2931 PCR tests may therefore be preferred as a more sensitive test compared with microscopy, even if immunofluorescence assays are used for microscopic examination.32 However, distinguishing between active disease and colonisation in immunocompromised patients may require quantitative PCR in some clinical circumstances.33

If sputum or lavage specimen analysis is inconclusive, transbronchial biopsy, transthoracic biopsy or even larger resections via thoracoscopic procedures, as in this case, may be needed for a definitive diagnosis.12 Although larger studies are needed, thoracic surgery appears generally safe in immunocompromised patients, with the benefits of establishing a definitive diagnosis likely outweighing the risks of surgery in many cases.34 However, a thorough discussion of the patient’s goals of care and prognosis from underlying immunocompromising conditions is of the utmost importance before pursuing such invasive procedures. Importantly, as demonstrated by Zhang et al,35 some cases of cavitary PJP lesions can be diagnosed without resorting to thoracoscopic biopsy, underscoring the importance of exhausting less invasive diagnostic approaches when clinically appropriate.

Treatment & Prophylaxis

Current guidelines for managing PJP in immunosuppressed patients on immunotherapeutic and molecular-targeted agents do not provide specific treatment algorithms.4 Although TMP-SMX is considered first-line therapy for PJP based on randomised trials in HIV-infected patients,36 alternative agents such as atovaquone or clindamycin plus primaquine may be used if TMP-SMX is contraindicated. Limited data suggest that outcomes for granulomatous PJP treatment may be comparable to those for other PJP infections.12

While severe PJP infections typically require 21 days of treatment, the optimal duration for granulomatous or cavitary PJP remains uncertain due to potentially higher organism burden and reduced drug penetration. In our case, treatment was extended to multiple months based on the patient’s immunocompromised state, extensive lung involvement and slow radiographic improvement. Although this approach led to improvement, such prolonged courses are not routine. Zhang et al35 reported successful treatment of cavitary PJP lesions with a standard 3-week course of TMP-SMX in a patient with common variable immune deficiency, suggesting that shorter courses may still be effective in some cases of granulomatous PJP infections.

The efficacy of steroids in preventing inflammatory damage in non-HIV-infected individuals with PJP remains uncertain.3739 Additionally, the benefits of ruxolitinib discontinuation in PJP infection are uncertain, given worsening haematologic disease activity can itself cause immunocompromise. Further complicating risk–benefit decisions, if ruxolitinib is stopped, there is a need to monitor closely for ruxolitinib discontinuation syndrome.40 There may be a benefit of rechallenging with ruxolitinib if it is temporarily discontinued to help resolve an infection.41

There are no specific guidelines for prophylaxis of PJP in patients on ruxolitinib. Green et al42 suggest that a PJP risk greater than 3.5% warrants prophylaxis in immunocompromised non-HIV-infected adults. Although the overall risk of PJP in patients with myelofibrosis taking ruxolitinib does not appear to reach this threshold,4 further studies are needed to understand the risk in subsets of patients with evidence of more severe immunosuppression such as prior opportunistic infections or severe cytopenias.

Patient’s perspective

The fungal infection I have been experiencing has made a difference in my health, initially causing many symptoms that truly affected me, chills, loss of appetite, shortness of breath, coughing, night sweats, loss of energy. Once I was diagnosed and doctors found medication, I gradually improved. Thanks so much for the care I received.

Learning points

In immunocompromised patients presenting with nodular or cavitary lesions, clinicians should consider Pneumocystis jirovecii pneumonia (PJP) in their differential diagnosis.

Parathyroid hormone-independent hypercalcaemia should prompt clinicians to consider granulomatous PJP in immunocompromised patients.

If initial diagnostics fail to confirm suspected granulomatous PJP, clinicians should weigh repeating less-invasive biopsy techniques against proceeding to potentially higher-yield thoracoscopic biopsies, considering the urgency for a definitive diagnosis.

The optimal duration of treatment for PJP infections causing necrotising granulomas warrants further investigation, with factors such as degree of immunosuppression and extent of infection potentially influencing the necessity for prolonged therapy.

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

Provenance and peer review: Not commissioned; externally peer reviewed.

Patient consent for publication: Consent obtained from next of kin.
==== Refs
References

1 Zhang SX Babady NE Hanson KE et al Recognition of diagnostic gaps for laboratory diagnosis of fungal diseases: expert opinion from the fungal diagnostics laboratories consortium (FDLC) J Clin Microbiol 2021 59 e01784-20 10.1128/JCM.01784-20 33504591
2 Tasaka S Recent advances in the diagnosis and management of Pneumocystis Pneumonia Tuberc Respir Dis (Seoul) 2020 83 132 40 10.4046/trd.2020.0015 32185915
3 Polverelli N Palumbo GA Binotto G et al Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients Hematol Oncol 2018 36 561 9 10.1002/hon.2509
4 Maschmeyer G De Greef J Mellinghoff SC et al Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) Leukemia 2019 33 844 62 10.1038/s41375-019-0388-x 30700842
5 Sadjadian P Wille K Griesshammer M Ruxolitinib-associated infections in polycythemia vera: Review of the literature, clinical significance, and recommendations Cancers (Basel) 2020 12 3132 10.3390/cancers12113132 33114733
6 Sayabovorn N Chongtrakool P Chayakulkeeree M Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review BMC Infect Dis 2021 21 27 27 10.1186/s12879-020-05703-2 33413168
7 Sepkowitz KA Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome Clin Infect Dis 2002 34 1098 107 10.1086/339548 11914999
8 Harpaz R Dahl RM Dooling KL Prevalence of immunosuppression among US adults, 2013 JAMA 2016 316 2547 8 10.1001/jama.2016.16477 27792809
9 Clark C Drummond RA The hidden cost of modern medical interventions: How medical advances have shaped the prevalence of human fungal disease Pathogens 2019 8 45 10.3390/pathogens8020045 30987351
10 Gadkowski LB Stout JE Cavitary pulmonary disease Clin Microbiol Rev 2008 21 305 33 10.1128/CMR.00060-07 18400799
11 Pyden AD VanderLaan PA Alonso CD et al Atypical histologic presentation of Pneumocystis pneumonia as granulomatous lung nodules Human Pathology: Case Reports 2021 23 200476 10.1016/j.ehpc.2021.200476
12 Hartel PH Shilo K Klassen-Fischer M et al Granulomatous reaction to pneumocystis jirovecii: clinicopathologic review of 20 cases Am J Surg Pathol 2010 34 730 4 10.1097/PAS.0b013e3181d9f16a 20414100
13 Pingili CS Sivapalan V PJP granuloma in an Immune competent host: Case report and literature review IDCases 2017 10 32 4 10.1016/j.idcr.2017.06.011 28856102
14 Pierre-Louis N Dlugos B A rare cause of cavitary lung lesions JAAPA 2017 30 28 31 10.1097/01.JAA.0000508206.48298.bc
15 Kanne JP Yandow DR Meyer CA Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection AJR Am J Roentgenol 2012 198 W555 61 W555 10.2214/AJR.11.7329 22623570
16 Hartel PH Granulomatous pulmonary Pneumocystis jirovecii in patients with solid and lymphoproliferative neoplasms: clinicopathologic characterization of 9 cases Radiology 2004 4 9
17 Ferré C Báguena F Podzamczer D et al Lung cavitation associated with Pneumocystis carinii infection in the acquired immunodeficiency syndrome: a report of six cases and review of the literature Eur Respir J 1994 7 134 9 10.1183/09031936.94.07010134 8143812
18 Dioverti MV Abu Saleh OM Tande AJ Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature Infect Dis (Lond) 2018 50 381 7 10.1080/23744235.2017.1390248 29251529
19 Lee SC Feenstra J Georghiou PR Pneumocystis jirovecipneumonitis complicating ruxolitinib therapy BMJ Case Rep 2014 2014 bcr2014204950 10.1136/bcr-2014-204950
20 Hu T Takamoto M Hida S et al IFN-gamma deficiency worsen Pneumocystis pneumonia with Th17 development in nude mice Immunol Lett 2009 127 55 9 10.1016/j.imlet.2009.08.013 19733591
21 Totet A Duwat H Magois E et al Similar genotypes of Pneumocystis jirovecii in different forms of Pneumocystis infection Microbiology (Reading) 2004 150 1173 8 10.1099/mic.0.26919-0 15133077
22 Matsuo K Miyake H Iwatsubo S et al Disseminated granulomatous Pneumocystis jirovecii pneumonia masquerading as miliary tuberculosis Infection 2023 51 545 7 10.1007/s15010-022-01868-x 35718842
23 To KKW Hung IFN Xu T et al Clinical significance of Pneumocystis jiroveci in patients with active tuberculosis Diagn Microbiol Infect Dis 2013 75 260 5 10.1016/j.diagmicrobio.2012.11.016 23333101
24 Wei S Lin L Pneumocystis jirovecii and Mycobacterium tuberculosis Pulmonary Coinfection in an HIV-Seronegative Patient: A Case Report and Literature Review Infect Drug Resist 2022 15 4149 54 10.2147/IDR.S370023 35937785
25 Yau AA Farouk SS Severe hypercalcemia preceding a diagnosis of Pneumocystis jirovecii pneumonia in a liver transplant recipient BMC Infect Dis 2019 19 739 739 10.1186/s12879-019-4370-z 31438872
26 Coche S Cornet G Morelle J et al Hypercalcemia associated with Pneumocystis jirovecii pneumonia in renal transplant recipients: case report and literature review Acta Clin Belg 2021 76 75 8 10.1080/17843286.2019.1655233 31470765
27 Hamroun A Lenain R Bui Nguyen L et al Hypercalcemia is common during Pneumocystis pneumonia in kidney transplant recipients Sci Rep 2019 9 12508 10.1038/s41598-019-49036-w 31467367
28 Del Corpo O Butler-Laporte G Sheppard DC et al Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis Clin Microbiol Infect 2020 26 1137 43 10.1016/j.cmi.2020.05.024 32479781
29 Senécal J Smyth E Del Corpo O et al Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis Clin Microbiol Infect 2022 28 23 30 10.1016/j.cmi.2021.08.017 34464734
30 Kiska DL Bartholoma NY Forbes BA Acceptability of low-volume, induced sputum specimens for diagnosis of Pneumocystis carinii pneumonia Am J Clin Pathol 1998 109 335 7 10.1093/ajcp/109.3.335 9495208
31 Limper AH Offord KP Smith TF et al Pneumocystis carinii pneumonia Am Rev Respir Dis 1989 140 1204 9 2817582
32 Chotiprasitsakul D Pewloungsawat P Setthaudom C et al Performance of real-time PCR and immunofluorescence assay for diagnosis of Pneumocystis pneumonia in real-world clinical practice PLoS One 2020 15 e0244023 10.1371/journal.pone.0244023 33347478
33 Morris A Norris KA Colonization by Pneumocystis jirovecii and its role in disease Clin Microbiol Rev 2012 25 297 317 10.1128/CMR.00013-12 22491773
34 Ellis ME Spence D Bouchama A et al Open lung biopsy provides a higher and more specific diagnostic yield compared to broncho-alveolar lavage in immunocompromised patients. Fungal Study Group Scand J Infect Dis 1995 27 157 62 10.3109/00365549509018998 7660081
35 Zhang Z Kern RM Joshi AY et al Cavitary lung lesions caused by Pneumocystis jirovecii in setting of common variable immune deficiency Respir Med Case Rep 2020 31 101277 10.1016/j.rmcr.2020.101277 33209577
36 McDonald EG Butler-Laporte G Del Corpo O et al On the treatment of Pneumocystis jirovecii pneumonia: current practice based on outdated evidence Open Forum Infect Dis 2021 8 ofab545 10.1093/ofid/ofab545 34988242
37 Moon SM Kim T Sung H et al Outcomes of moderate-to-severe Pneumocystis Pneumonia treated with adjunctive steroid in non-HIV-infected patients Antimicrob Agents Chemother 2011 55 4613 8 10.1128/AAC.00669-11 21788460
38 Delclaux C Zahar JR Amraoui G et al Corticosteroids as adjunctive therapy for severe Pneumocystis carinii Pneumonia in non-human immunodeficiency virus-infected patients: Retrospective study of 31 patients Clin Infect Dis 1999 29 670 2 10.1086/598651 10530464
39 Pareja JG Garland R Koziel H Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia Chest 1998 113 1215 24 10.1378/chest.113.5.1215 9596297
40 Palandri F Palumbo GA Elli EM et al Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis Blood Cancer J 2021 11 4 10.1038/s41408-020-00392-1 33414394
41 Palandri F Breccia M Bonifacio M et al Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis Cancer 2020 126 1243 52 10.1002/cncr.32664 31860137
42 Green H Paul M Vidal L et al Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials Mayo Clin Proc 2007 82 1052 9 10.4065/82.9.1052 17803871
